Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer https://www.issuewire.com/manhattan-biosolutions-enters-into-collaboration-agreements-with-the-nih-and-binghamton-university-to-develop-novel-adc-1781455477718844 New York City, New York Nov 2, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, today announced a […]
Mbio2018
https://www.issuewire.com/manhattan-biosolutions-inc-selected-to-be-featured-in-new-york-pavilion-at-bio-international-convention-1766550010501619 New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of precision biologics for the treatment of age-related diseases, announced that it has been chosen to participate in the New York State pavilion at the BIO International Convention, the […]
https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license agreements with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to generate and validate novel antibody-drug conjugate (ADC) therapies using monoclonal […]
https://www.accesswire.com/703518/Manhattan-BioSolutions-Enters-into-a-Research-Collaboration-And-License-Option-Agreement-with-Binghamton-University-for-the-New-Linker-Payload-Technology NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics for the treatment of advanced and metastatic cancers, today announced a multitarget research and development collaboration and license option agreement with Binghamton University. The collaboration will utilize […]
https://www.24-7pressrelease.com/press-release/489820/manhattan-biosolutions-announces-grant-award-from-the-university-at-buffalo-center-for-advanced-technology-in-big-data-and-health-sciences Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, NY, March 23, 2022 /24-7PressRelease/ — Manhattan BioSolutions, Inc, an emerging biotechnology company developing a new class of targeted immunotherapies for the treatment of advanced and metastatic cancers, has been […]
Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for the treatment of advanced and metastatic cancers, has been awarded grant funding as part of Round 3 of the New Jersey Commission on Science, Innovation, and Technology Direct Financial […]
New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and Manhattan BioSolutions, an emerging biotechnology company developing immunoregulatory therapies for the treatment of metastatic cancers, have been awarded a grant from the University at Buffalo Center for […]
New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies for the treatment of metastatic cancers, today announced positive preclinical data from its in vivo efficacy study in a mouse model of bladder cancer. These data validate the key advantages […]
NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery of the immunoregulatory therapies for the treatment of metastatic cancers, today announced that it will be participating at the “ACCESS CHINA Forum @ JPM WEEK 2021” which will […]